Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.125
Bid: 8.00
Ask: 8.25
Change: 0.00 (0.00%)
Spread: 0.25 (3.125%)
Open: 8.125
High: 8.125
Low: 8.125
Prev. Close: 8.125
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IXICO to Present at 10th Annual CNS Summit 2019

30 Oct 2019 09:00

RNS Number : 5364R
IXICO plc
30 October 2019
 

30 October 2019

 

IXICO plc

("IXICO" or the "Company")

 

IXICO to Present at 10th Annual CNS Summit 2019

 

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces that it is scheduled to attend and present at the 10th Annual CNS Summit held from 31st October to 3rd November 2019 in Boca Raton, Florida, USA.

10th Annual CNS Summit 

31st October - 3rd November 2019, Boca Raton Resort, Florida, USA

 

Robin Wolz, Senior Vice President of Science & Innovation at IXICO will present a poster entitled "Automated sleep-wake prediction from wearable sensors using neural networks - from data collection to algorithm development, cross-validation and clinical trial deployment" during the evening receptions on Friday 1st and Saturday 2nd November 2019.

This study shows how AI technology improved the analysis of sleep/wake accelerometry from wearables compared to traditional, count-based measurements in a robust and reproducible way. Thus, the exploratory use of this validated algorithm in clinical trials is feasible and provides the collection of evidence needed to support further development of real-world evidence in clinical trial designs. 

The rise in people using connected wearable devices has opened the door for the medical field to harness real-time patient health data to support clinical development of many diseases including Alzheimer's and Parkinson's disease.

Founded by R&D leaders, the CNS Summit is a platform of industry leaders working collaboratively to shape the future of the life sciences with a focus on innovation and technology. The agenda features top leaders from the regulators, pharmaceutical and biotech companies, technology and services companies driving change in the healthcare sector.

Poster authors:

Robin Wolz1,2, Luis Peraza1, Richard Joules1, Yves Dauvilliers3

Affiliations: 1- IXICO, London, UK, 2- Imperial College London, London, UK, 3- Department Neurology, Centre Hospitalier Universitaire, Montpellier, France

 

For further information please contact:

IXICO plc

+44 (0) 20 3763 7498

Giulio Cerroni, Chief Executive Officer

 

Optimum Strategic Communications

 +44 (0) 203 950 9144

Mary Clark / Supriya Mathur / Manel Mateus

 

IXICO@optimumcomms.com

 

 

About IXICO

 

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease.

 

Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience and rare disease, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

 

More information is available on www.IXICO.com

 

About CNS Summit

 

CNS Summit is a platform for change and a community passionate about shaping the future, with a focus on collaboration, innovation, and technology. Its mission is to have a positive impact on the success of clinical development programs. CNS Summit believes this mission is its ethical duty to the patients they serve by developing new treatments.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABRBDGXXDBGCC
Date   Source Headline
28th Nov 201110:09 amRNSDirector/PDMR Shareholding
28th Nov 201110:08 amRNSDirector/PDMR Shareholding
24th Nov 20117:00 amRNSFinal Results
7th Nov 20118:51 amRNSBlocklisting Interim Review
4th Oct 20117:00 amRNSResearch Update
29th Sep 20117:00 amRNSResearch Update
16th Aug 20117:00 amRNSInterim Management Statement
28th Jul 20117:31 amRNSResearch Update
12th Jul 201112:04 pmRNSBlocklisting Interim Review
5th Jul 201112:04 pmRNSTotal Voting Rights
17th Jun 20113:28 pmRNSBlocklisting Interim Review
26th May 20117:00 amRNSHalf Yearly Report
17th May 20118:35 amRNSNotice of Results
5th May 20117:00 amRNSBlocklisting Interim Review
31st Mar 20119:07 amRNSResult of AGM
2nd Mar 201112:27 pmRNSHolding(s) in Company
15th Feb 20117:00 amRNSInterim Management Statement
7th Feb 201112:18 pmRNSAnnual Information Update
1st Feb 20118:54 amRNSTotal Voting Rights
1st Feb 20118:53 amRNSAnnual Financial Report & Notice of AGM
19th Jan 20112:14 pmRNSDirector/PDMR Shareholding
19th Jan 20112:14 pmRNSDirector/PDMR Shareholding
14th Jan 201110:18 amRNSHolding(s) in Company
10th Jan 201111:45 amRNSHolding(s) in Company
7th Jan 20111:50 pmRNSBlock Listing Application
7th Jan 201110:59 amRNSBlocklisting Application
4th Jan 20112:01 pmRNSTotal Voting Rights
21st Dec 201012:19 pmRNSDirector/PDMR Shareholding
21st Dec 201012:18 pmRNSDirector/PDMR Shareholding
14th Dec 20101:15 pmRNSBlock Listing Application
30th Nov 20107:00 amRNSFinal Results
17th Nov 201011:44 amRNSResearch Update
3rd Nov 20109:29 amRNSBlocklisting Interim Review
1st Nov 20104:31 pmRNSPreliminary Results - Change of Date
1st Nov 201010:41 amRNSNotice of Results
29th Sep 20102:00 pmRNSPresents Cogane data at scientific conferences
18th Aug 20107:00 amRNSInterim Management Statement
22nd Jul 20101:49 pmRNSDirector/PDMR Shareholding
22nd Jul 20101:49 pmRNSDirector/PDMR Shareholding
5th Jul 201010:59 amRNSChange of Registered Office
21st Jun 20107:00 amRNSAppointment of Chief Executive Officer
14th Jun 20107:00 amRNSRegulatory Approval to Begin Cogane PII Trial
24th May 20107:00 amRNSHalf Yearly Report
19th May 20104:25 pmRNSNotice of Results
4th May 20102:13 pmRNSBlocklisting Interim Review
1st Apr 201012:36 pmRNSDirector/PDMR Shareholding
1st Apr 201012:35 pmRNSDirector/PDMR Shareholding
1st Apr 201012:34 pmRNSDirector/PDMR Shareholding
31st Mar 201012:19 pmRNSResult of AGM
2nd Mar 20108:25 amRNSNotice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.